Use of follow-on fingolimod for multiple sclerosis: Analysis of effectiveness and patient reported outcomes in a real-world clinical setting

Basit Öğe Kaydı
dc.authoridKoseoglu, Mesrure/0000-0003-0469-0064
dc.authoridUNAL, Aysun/0000-0002-7702-8437
dc.authoridKOTAN, DILCAN/0000-0002-3101-4742
dc.contributor.authorAltunan, Bengu
dc.contributor.authorUnal, Aysun
dc.contributor.authorEfendi, Husnu
dc.contributor.authorKoseoglu, Mesrure
dc.contributor.authorTerzi, Murat
dc.contributor.authorKotan, Dilcan
dc.contributor.authorTamam, Yusuf
dc.date.accessioned2024-10-29T17:58:28Z
dc.date.available2024-10-29T17:58:28Z
dc.date.issued2023
dc.departmentTekirdağ Namık Kemal Üniversitesien_US
dc.description.abstractBackground: Follow-on disease modifying therapies (FO-DMTs) do not always require Phase III studies. There are concerns that cheaper FO-DMTs are only used to reduce healthcare costs. However, the well-being of people with MS (pwMS) should be a priority. We aimed to evaluate the efficacy, safety and treatment satisfaction of one of the FO-Fingolimod (FTY) used in Turkey with the approval of Turkish Ministry of Health.Methods: PwMS under FTY were recruited from 13 centers and real-world data and answers of satisfaction and adherence statements of pwMS on FTY treatment were analyzed.Results: Data of 239 pwMS were obtained. The duration of FTY treatment was 2.5 & PLUSMN; 0.8 (1-4) years in pwMS who were included in the study and whose treatment continued for at least one year. Significant decreases in annual relapse rate (p < 0.001), Expanded Disability Status Scale (p < 0.001) and neuroimaging findings (p < 0.001) were observed. While 64% of the patients were satisfied and 71.5% were found to adherent with this FO-FTY.Conclusion: This multicenter retrospective study found that the efficacy, safety and treatment adherence of a prescribed FO-FTY were consistent with the results of real-world studies. Studies including real-world data may provide guidance to address issues related to FO-FTY use.en_US
dc.identifier.doi10.1016/j.msard.2023.104880
dc.identifier.issn2211-0348
dc.identifier.issn2211-0356
dc.identifier.pmid37459716en_US
dc.identifier.scopus2-s2.0-85165251046en_US
dc.identifier.urihttps://doi.org/10.1016/j.msard.2023.104880
dc.identifier.urihttps://hdl.handle.net/20.500.11776/14335
dc.identifier.volume77en_US
dc.identifier.wosWOS:001039758400001en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Sci Ltden_US
dc.relation.ispartofMultiple Sclerosis and Related Disordersen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectFollow-on drugen_US
dc.subjectGeneric fingolimoden_US
dc.subjectReal-world dataen_US
dc.subjectEfficacyen_US
dc.subjectSafetyen_US
dc.subjectSatisfactionen_US
dc.subjectAdherenceen_US
dc.titleUse of follow-on fingolimod for multiple sclerosis: Analysis of effectiveness and patient reported outcomes in a real-world clinical settingen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu